Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support—Results of a Prospective, Randomized, Comparative Study

Table 3

Main characteristics of trials on the use of a single injection of GnRH agonist for luteal phase support.

Trial	Study design	Stimulation protocol	Ovulation trigger	Luteal phase support			Day of ET	Implantation rate (study group/control group)	(Ong/Clin) Pregnancy rate (study group/control group)
				Study group; GnRH-a	Control group	Other concomitant medications; (all patients)
Tesarik et al. [7]	RCT	GnRH-a long; GnRH-antag	250 µg r-hCG	: 150 GnRH-a long; : 150 GnRH-antag; 0.1 mg/triptorelin; Single injection D6 after OPU	: 150 GnRH-a long; : 150 GnRH-antag; Placebo	Vaginal micronized progesterone (400 mg/d) + estradiol valerate (4 mg/d) + r-hCG (250 µg; single dose on d of ET)	Day 3	GnRH-a long: 29.8%; 18.2%; (); GnRH-antag: 27.1%; 17.4%; ()	GnRH-a long: Ong PR/Tf: 46.8%; 38.0%; (NS); GnRH-antag: Ong PR/Tf: 44.8%; 31.9%; ()
Ata et al. [16]	RCT	GnRH-a long	10.000 IU u-hCG	: 285; 0.1 mg/triptorelin; Single injection D6 after OPU	: 285; Placebo	Vaginal micronized progesterone gel (90 mg/d)	Day 3	21.1%; 20.1%; (NS)	Ong PR: 31.2%; 29.5%; (NS)
Isik et al. [11]	RCT	GnRH-antag	10.000 IU u-hCG; or 250 µg r-hCG	: 74; 0.5 mg/leuprolide; Single injection D6 after OPU	: 80; No placebo	Vaginal micronized progesterone (600 mg/d) + hCG (single dose)	Day 3	26.5%; 9.3%; ()	Clin PR: 40.5%; 20.0%; ()
Razieh et al. [10]	RCT	GnRH-a long	10.000 IU u-hCG	: 90; 0.1 mg/triptorelin; Single injection D5 or D6 after OPU	: 90; Placebo	Vaginal micronized progesterone (800 mg/d)	Days 2-3	12.3%; 7.3%; ()	Clin PR: 25.5%; 10.0%; ()
Ata and Urman [17]	RCT	GnRH-antag	10.000 IU u-hCG	: 38; 0.1 mg/triptorelin; Single injection D6 after OPU	: 52; Placebo	Vaginal micronized progesterone gel (90 mg/d)	Day 3	14.12%; 27.27% ()	Ong PR: 18.4%; 42.31%; ()
Kung et al. [13]	Retrospective study	GnRH-a long; GnRH-antag	500 µg r-hCG	: 147; 0.1 mg/triptorelin; Single injection D6 after OPU	: 93; No GnRH-a	Vaginal micronized progesterone gel (90 mg/d); or i.m. progesterone (25–50 mg/d)	Days 3–5	24.5%; 17.0%; ()	Clin PR: 49.0%; 33.3%; ()
Yıldız et al. [14]	RCT	GnRH-a long	10.000 IU u-hCG	: 100; 1 mg/leuprolide acetate; Single injection D6 after OPU	: 95; No placebo	Vaginal micronized progesterone (600 mg/d) + 17β estradiol (4 mg/d)	Day 3	20.7%; 13.3%; (NS)	Ong PR: 36.0%; 27.4%; (NS)